These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://alyshanlcb516897.glifeblog.com/37823255/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide